Author: Kelsey Kaustinen | Dublin, Ohio (April 2013) – The Ohio State University (OSU) and Biosortia Pharmaceuticals have found that a great industry partner can be just down the street. The two Dublin, Ohio-based organizations have established an agreement to discover new biologically active natural products that demonstrate potential anti-cancer activity.

Biosortia will be sponsoring the research project, and compounds that result from the agreement will be tested primarily against human colon cancer assays, though it may eventually expand to include other cancer subtypes. Ultimately, the partners hope to identify lead compounds that can be licensed through Biosortia´s industry relationships to pharmaceutical companies for further development. The initial agreement was finalized by a collaboration between OSU´s Technology Commercialization and Knowledge Transfer Office and Office of Sponsored Programs.